Sedana Medical Logo

Sedana Medical

ISIN

SE0015988373

Ticker

SEDANA

Sector

Health Care

Sub-Industry

Pharmaceuticals

Country

Sweden

Year Founded

1999

About Sedana Medical

Company Description

Sedana Medical is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient’s life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical product Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.

Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordic, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.

Sedana Medical was founded in 2005, is listed on Nasdaq Stockholm and is headquartered in Stockholm, Sweden.

Headcount

85

Served Area

Worldwide

Headquarters

Vendevägen 89
18232, Danderyd
Sweden

Financial statements

Download as Excel
Line item in (sek) 01.01.2021 01.01.2022 01.01.2023
Assets N/A 1,167,580,000.00 1,081,588,000.00
Noncurrent Assets N/A 286,839,000.00 408,172,000.00
Machinery N/A 1,309,000.00 955,000.00
Copyrights Patents And Other Industrial Property Rights Service And Operating Rights N/A 1,786,000.00 2,849,000.00
Deferred Tax Assets N/A 23,000.00 29,000.00
Other Noncurrent Financial Assets N/A 42,000.00 46,000.00
Current Assets N/A 880,741,000.00 673,416,000.00
Inventories N/A 11,093,000.00 38,597,000.00
Current Trade Receivables N/A 20,345,000.00 15,849,000.00
Current Prepayments And Current Accrued Income Other Than Current Contract Assets N/A 7,115,000.00 6,017,000.00
Current Tax Assets Current N/A 410,000.00 514,000.00
Other Current Nonfinancial Assets N/A 5,597,000.00 4,697,000.00
Cash 376,171,000.00 836,181,000.00 607,742,000.00
Equity And Liabilities N/A 1,167,580,000.00 1,081,588,000.00
Equity 551,094,000.00 1,101,456,000.00 1,029,156,000.00
Issued Capital N/A 2,483,000.00 2,483,000.00
Retained Earnings N/A -123,606,000.00 -197,113,000.00
Additional Paidin Capital N/A 1,222,395,000.00 1,226,435,000.00
Equity Attributable To Owners Of Parent N/A 1,101,456,000.00 1,029,155,000.00
Liabilities N/A 66,124,000.00 52,433,000.00
Noncurrent Liabilities N/A 4,642,000.00 3,576,000.00
Current Liabilities N/A 61,482,000.00 48,857,000.00
Trade And Other Current Payables To Trade Suppliers N/A 15,036,000.00 11,270,000.00
Current Accruals And Current Deferred Income Including Current Contract Liabilities N/A 19,744,000.00 22,932,000.00
Current Tax Liabilities Current N/A 3,997,000.00 2,559,000.00
Other Current Liabilities N/A 18,473,000.00 6,929,000.00
Line item in (sek) 01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue From Sale Of Goods 159,152,000.00 122,865,000.00
Other Income 4,013,000.00 13,319,000.00
Profit Loss From Operating Activities -61,493,000.00 -105,887,000.00
Finance Income 11,285,000.00 48,300,000.00
Finance Costs 7,163,000.00 15,346,000.00
Profit Loss Before Tax -57,371,000.00 -72,933,000.00
Income Tax Expense Continuing Operations 595,000.00 574,000.00
Profit Loss Attributable To Owners Of Parent -57,966,000.00 -73,507,000.00
Line item in (sek) 01.01.2022 01.01.2023
Adjustments For Decrease Increase In Inventories -2,296,000.00 -27,504,000.00
Adjustments For Unrealised Foreign Exchange Losses Gains -4,080,000.00 -863,000.00
Interest Paid Classified As Operating Activities 243,000.00 255,000.00
Interest Received Classified As Operating Activities 0.00 3,580,000.00
Cash Flows From Used In Operating Activities -41,221,000.00 -115,433,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities 5,192,000.00 735,000.00
Purchase Of Intangible Assets Classified As Investing Activities 105,063,000.00 137,048,000.00
Cash Flows From Used In Investing Activities -110,255,000.00 -137,783,000.00
Proceeds From Issuing Shares 614,900,000.00 0.00
Proceeds From Issuing Other Equity Instruments 1,696,000.00 3,590,000.00
Payments Of Other Equity Instruments 0.00 490,000.00
Payments Of Lease Liabilities Classified As Financing Activities 3,579,000.00 4,510,000.00
Other Inflows Outflows Of Cash Classified As Financing Activities 0.00 -97,000.00
Cash Flows From Used In Financing Activities 605,071,000.00 -1,507,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes 453,595,000.00 -254,722,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents 6,415,000.00 26,283,000.00

Please note that some sums might not add up.

Filings & Publications

  • Consolidated Report 2022 - Q4 Swedish 🇸🇪 Published: 09.05.2023

Insider Trades

Date Trading entity / Person Association Trade type Volume
29.08.2022 Christoffer Björn Rosenblad Other Buy SEK 232,000.00
29.08.2022 Christoffer Björn Rosenblad Other Sell SEK 115,000.00
21.07.2022 Hilde Furberg Other Buy SEK 64,288.44
28.04.2022 Johan Spetz Other Buy SEK 223,615.21
28.04.2022 Johannes Doll Other Buy SEK 209,520.60
28.04.2022 Christoffer Björn Rosenblad Other Buy SEK 161,400.00
03.12.2021 Johannes Doll Other Buy SEK 1,000,180.00
20.09.2021 Ola Gunnar Magnusson Other Sell SEK 2,943,000.00

Capital Markets Information

ISIN

SE0015988373

LEI

549300FQ3NJRI56LCX32

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

Nasdaq Stockholm

Contact Investor Relations Department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.